Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and a heterogeneous B-cell disease. The majority of patients with newly diagnosed disease are cured with first-line combination immunochemotherapy treatment however, those who experience treatment failure have dismal outcomes. Antibody therapies and immunotherapy have provided the single most major advance in the treatment of DLBCL in the last 4 decades. Rituximab, the first immunotherapy, and a monoclonal antibody targeting CD20, improved DLBCL overall survival when added to chemotherapy 2 decades ago. Since then, the advent of further "naked" monoclonal antibodies that target malignant B-cells or stimulate the immune system to kill cancer, as well as antibody-drug conjugates and bispecific antibodies have all entered the DLBCL armamentarium; with 5 antibody therapy approvals in the last 6 years alone. Here we review the literature on antibodies and immunotherapies for DLBCL and the future directions involving this successful group of drugs.

中文翻译：

---

弥漫性大 B 细胞淋巴瘤的抗体和免疫治疗


弥漫性大 B 细胞淋巴瘤 (DLBCL) 是最常见的淋巴瘤，也是一种异质性 B 细胞疾病。大多数新诊断疾病的患者都可以通过一线联合免疫化疗治疗治愈，但治疗失败的患者结局却很惨淡。过去 4 年来，抗体疗法和免疫疗法为 DLBCL 的治疗带来了最重大的进展。利妥昔单抗是第一种免疫疗法，也是一种靶向 CD20 的单克隆抗体，20 年前添加到化疗中时，改善了 DLBCL 的总体生存率。从那时起，更多针对恶性 B 细胞或刺激免疫系统杀死癌症的“裸”单克隆抗体以及抗体药物缀合物和双特异性抗体的出现都已进入 DLBCL 武器库；仅在过去 6 年里就有 5 个抗体疗法获得批准。在这里，我们回顾了有关 DLBCL 的抗体和免疫疗法的文献，以及涉及这组成功药物的未来方向。